MedTrace Logo

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.

Conditions

  • High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

Interventions

DRUG

nab-sirolimus

nab-sirolimus, single agent

DRUG

nab-sirolimus + temozolomide

temozolomide, combination

DRUG

nab-sirolimus + bevacizumab

bevacizumab, combination

DRUG

nab-sirolimus + lomustine

lomustine, combination

DRUG

nab-sirolimus + marizomib (MRZ)

marizomib (MRZ), combination

DRUG

nab-sirolimus + temozolomide + radiotherapy

temozolomide + radiotherapy, combination

Sponsors & Collaborators

  • Aadi Bioscience, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2022-08-26
Completion
2022-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463265 on ClinicalTrials.gov